Literature DB >> 12097247

In vitro cultivation of cryptosporidium species.

Michael J Arrowood1.   

Abstract

The in vitro cultivation of protozoan parasites of the genus Cryptosporidium has advanced significantly in recent years. These obligate, intracellular parasites colonize the epithelium of the digestive and respiratory tracts, are often difficult to obtain in significant numbers, produce durable oocysts that defy conventional chemical disinfection methods, and are persistently infectious when stored at refrigerated temperatures (4 to 8 degrees C). While continuous culture and efficient life cycle completion (oocyst production) have not yet been achieved in vitro, routine methods for parasite preparation and cell culture infection and assays for parasite life cycle development have been established. Parasite yields may be limited, but in vitro growth is sufficient to support a variety of research studies, including assessing potential drug therapies, evaluating oocyst disinfection methods, and characterizing life cycle stage development and differentiation.

Entities:  

Mesh:

Year:  2002        PMID: 12097247      PMCID: PMC118076          DOI: 10.1128/CMR.15.3.390-400.2002

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  54 in total

1.  In vitro cultivation of Cryptosporidium parvum and screening for anticryptosporidial drugs.

Authors:  V McDonald; R Stables; D C Warhurst; M R Barer; D A Blewett; H D Chapman; G M Connolly; P L Chiodini; K P McAdam
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

2.  Cryptosporidium parvum: culture in MDCK cells.

Authors:  M J Rosales; J Cifuentes; C Mascaró
Journal:  Exp Parasitol       Date:  1993-03       Impact factor: 2.011

3.  Studies on cryopreservation of Cryptosporidium parvum.

Authors:  R Fayer; T Nerad; W Rall; D S Lindsay; B L Blagburn
Journal:  J Parasitol       Date:  1991-06       Impact factor: 1.276

4.  In vitro multiplication of Cryptosporidium parvum in mouse peritoneal macrophages.

Authors:  F Martinez; C Mascaro; M J Rosales; J Diaz; J Cifuentes; A Osuna
Journal:  Vet Parasitol       Date:  1992-04       Impact factor: 2.738

5.  Anti-Cryptosporidium parvum antibodies inhibit infectivity in vitro and in vivo.

Authors:  P S Doyle; J Crabb; C Petersen
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

6.  Microtubule inhibitors block Cryptosporidium parvum infection of a human enterocyte cell line.

Authors:  P M Wiest; J H Johnson; T P Flanigan
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

7.  Cryptosporidium parvum infection of intestinal epithelium: morphologic and functional studies in an in vitro model.

Authors:  R B Adams; R L Guerrant; S Zu; G Fang; J K Roche
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

8.  Complete development of Cryptosporidium parvum in a human endometrial carcinoma cell line.

Authors:  K R Rasmussen; N C Larsen; M C Healey
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

9.  Effects of carbohydrates and lectins on cryptosporidial sporozoite penetration of cultured cell monolayers.

Authors:  T L Kuhls; D A Mosier; D L Crawford
Journal:  J Protozool       Date:  1991 Nov-Dec

10.  Cryptosporidium parvum: in vitro cultivation in Madin-Darby canine kidney cells.

Authors:  J Gut; C Petersen; R Nelson; J Leech
Journal:  J Protozool       Date:  1991 Nov-Dec
View more
  34 in total

1.  Evaluation of recombinant oocyst protein CP41 for detection of cryptosporidium-specific antibodies.

Authors:  Sonia A Kjos; Mark Jenkins; Pablo C Okhuysen; Cynthia L Chappell
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

Review 2.  Susceptibility Testing of Medically Important Parasites.

Authors:  Abebe Genetu Bayih; Anjan Debnath; Edward Mitre; Christopher D Huston; Benoît Laleu; Didier Leroy; Benjamin Blasco; Brice Campo; Timothy N C Wells; Paul A Willis; Peter Sjö; Wesley C Van Voorhis; Dylan R Pillai
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

3.  Development and validation of a cell culture based assay for in vitro assessment of anticryptosporidial compounds.

Authors:  M Najdrowski; A R Heckeroth; C Wackwitz; S Gawlowska; U Mackenstedt; D Kliemt; A Daugschies
Journal:  Parasitol Res       Date:  2007-01-10       Impact factor: 2.289

4.  Cryptosporidium parvum Elongation Factor 1α Participates in the Formation of Base Structure at the Infection Site During Invasion.

Authors:  Xue Yu; Fengguang Guo; Rola Barhoumi Mouneimne; Guan Zhu
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

5.  Detection of viable Cryptosporidium parvum in soil by reverse transcription-real-time PCR targeting hsp70 mRNA.

Authors:  Zhanbei Liang; Ann Keeley
Journal:  Appl Environ Microbiol       Date:  2011-07-29       Impact factor: 4.792

Review 6.  A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.

Authors:  William Checkley; A Clinton White; Devan Jaganath; Michael J Arrowood; Rachel M Chalmers; Xian-Ming Chen; Ronald Fayer; Jeffrey K Griffiths; Richard L Guerrant; Lizbeth Hedstrom; Christopher D Huston; Karen L Kotloff; Gagandeep Kang; Jan R Mead; Mark Miller; William A Petri; Jeffrey W Priest; David S Roos; Boris Striepen; R C Andrew Thompson; Honorine D Ward; Wesley A Van Voorhis; Lihua Xiao; Guan Zhu; Eric R Houpt
Journal:  Lancet Infect Dis       Date:  2014-09-29       Impact factor: 25.071

7.  Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth.

Authors:  Kovi Bessoff; Adam Sateriale; K Kyungae Lee; Christopher D Huston
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

8.  Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.

Authors:  Cristina Rueda; Soledad Fenoy; Fernando Simón; Carmen Del Aguila
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

9.  Targeting a prokaryotic protein in a eukaryotic pathogen: identification of lead compounds against cryptosporidiosis.

Authors:  Nwakaso N Umejiego; Deviprasad Gollapalli; Lisa Sharling; Anna Volftsun; Jennifer Lu; Nicole N Benjamin; Adam H Stroupe; Thomas V Riera; Boris Striepen; Lizbeth Hedstrom
Journal:  Chem Biol       Date:  2008-01

10.  Effect of select medium supplements on in vitro development of Cryptosporidium andersoni in HCT-8 cells.

Authors:  Liang Wu; Sheng-xia Chen; Xu-gan Jiang; Yu-juan Shen; Zhao-xi Lu; Guo-hua Tu; Xing-li Fu; Jian-ping Cao
Journal:  Parasitol Res       Date:  2009-07-30       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.